About
Combining monoclonal antibodies (mAb) targeting cancer-specific antigen with cytotoxin has revealed great potential as a novel targeted cancer therapy. Antibody-drug conjugates (ADCs) are a new class of therapeutic agents that contain the targeting ability of mAbs with small molecular drugs. Due to the significant differences in antibody drug conjucates, including the differences in recognition sites, connection sites, linker design, and small-molecule toxins, the ADCs drugs' overall efficacies and toxicities of the same target may not be the same. The complete development process of ADCs drugs from preclinical to clinical involves target verification, process characterization, preclinical efficacy and safety evaluation, pharmacokinetic model, clinical design, and